Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients

1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline2. Feng, RM, Zong, YN, Cao, SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019; 39: 22.
Google Scholar | Crossref | Medline3. Heinemann, V, von Weikersthal, LF, Decker, T, et al. FOLFIRI plus cetuximabversus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065–1075.
Google Scholar | Crossref | Medline | ISI4. Van Cutsem, E, Köhne, CH, Láng, I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011–2019.
Google Scholar | Crossref | Medline | ISI5. Loupakis, F, Cremolini, C, Masi, G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609–1618.
Google Scholar | Crossref | Medline | ISI6. Zhang, Y, Chen, Z, Li, J. The current status of treatment for colorectal cancer in China: A systematic review. Medicine (Baltimore). 2017; 96: e8242.
Google Scholar7. Xu, RH , et al. CSCO poster: 1490 (2018).
Google Scholar8. Chen, J, Guo, F, Shi, X, et al. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 2014; 14: 802.
Google Scholar | Crossref | Medline9. De Roock, W, De Vriendt, V, Normanno, N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011, 12: 594–603.
Google Scholar | Crossref | Medline | ISI10. Allegra, CJ, Jessup, JM, Somerfield, MR, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti epidermal growth factor receptor monoclonal antibody therapy. J ClinOncol 2009; 27: 2091–2096.
Google Scholar | Crossref | Medline | ISI11. Richman, SD, Seymour, MT, Chambers, P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931–5937.
Google Scholar | Crossref | Medline | ISI12. Roth, AD, Tejpar, S, Delorenzi, M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28: 466–474.
Google Scholar | Crossref | Medline | ISI13. Li, Z, Chen, Y, Wang, D, et al. Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. J Int Med Res 2012, 40: 1589–1598.
Google Scholar | SAGE Journals | ISI14. Guo, TA, Wu, YC, Tan, C, et al. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Int J Cancer 2019; 145: 1625–1634.
Google Scholar | Crossref | Medline15. Taieb, J, Zaanan, A, Le Malicot, K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage iii colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol 2016; 2: 643–653.
Google Scholar | Crossref | Medline16. Modest, DP, Ricard, I, Heinemann, V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 2016; 27: 1746–1753.
Google Scholar | Crossref | Medline17. Chen, J, Guo, F, Shi, X, et al. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 2014; 14: 802.
Google Scholar | Crossref | Medline18. Ye, ZL, Qiu, MZ, Tang, T, et al. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis. Cancer Med 2020; 9: 745–756.
Google Scholar | Crossref | Medline19. Roth, AD, Tejpar, S, Delorenzi, M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466–474.
Google Scholar | Crossref | Medline | ISI20. Andreyev, HJ, Norman, AR, Cunningham, D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 2001; 85: 692–696.
Google Scholar | Crossref | Medline | ISI21. De Roock, W, Claes, B, Bernasconi, D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753–762.
Google Scholar | Crossref | Medline | ISI22. Vaughn, CP, Zobell, SD, Furtado, LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307–312.
Google Scholar | Crossref | Medline | ISI23. Shen, Y, Wang, J, Han, X, et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 2013; 8: e81628.
Google Scholar | Crossref24. Misale, S, Yaeger, R, Hobor, S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532–536.
Google Scholar | Crossref | Medline | ISI25. Karapetis, CS, Khambata-Ford, S, Jonker, DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–1765.
Google Scholar | Crossref | Medline | ISI26. De Roock, W, Jonker, DJ, Di Nicolantonio, F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812–1820.
Google Scholar | Crossref | Medline | ISI27. Rowland, A, Dias, MM, Wiese, MD, et al. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer 2016; 55: 122–130.
Google Scholar | Crossref | Medline | ISI28. Peeters, M, Douillard, JY, Van Cutsem, E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759–765.
Google Scholar | Crossref | Medline | ISI

留言 (0)

沒有登入
gif